Articles

Find an Article

Filter articles

Applied Filters

Showing 81 to 90 of 314 results

Eli Lilly: the trials and tribulations of antibody patents

17-04-2018

Courts have not always been able to appreciate the complexities around antibody patents, causing problems for innovation and investment, says Eli Lilly patent counsel Duane Marks in an interview with LSIPR.

AstraZeneca: no time for time-wasting

US08-03-2018

The IP team at AstraZeneca must “ruthlessly” prioritise how it spends time and resources, its vice president of global IP explained in an interview.

Getting into the biosimilars action

US06-03-2018Henk Heus and Ellen Sherin

The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.

The licensing landscape at Pieris

US22-02-2018

Forming licensing agreements with other pharmaceutical companies is an important part of Pieris’s strategy, according to Ahmed Mousa, vice president of licensing, IP and legal affairs at the clinical-stage company.

A helping hand for rare diseases

US08-02-2018

Companies researching and commercialising drugs for rare diseases face unusual challenges in protecting their inventions, as Michael Yamauchi, director and patent counsel at Alexion Pharmaceuticals, tells LSIPR in an interview.

LSIPR 50 2017: Leda Trivinos—Playing the long game

US10-11-2017

Thinking about how IP can assist a company long before it has fully developed is essential, says Leda Trivinos of Flagship Pioneering in an interview with LSIPR.

LSIPR 50 2017: James Topper—Venturing into biotech

US10-11-2017

Frazier Healthcare Partners has been responsible for creating and investing in multiple biotech companies, developing products from novel antibiotics to cancer therapies. James Topper, Frazier’s managing general partner, explains the firm’s philosophy.

LSIPR 50 2017: Carl Gordon—Realising great ideas

US10-11-2017

Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR.

LSIPR 50 2017: Lars Kellberg—The challenge of IPRs

US10-11-2017

In the current IP landscape it is wise to be prepared for attacks on important patents, as Lars Kellberg, corporate vice president and corporate patents of Novo Nordisk, explains to LSIPR.

LSIPR 50 2017: Larry Coury—The art of successful litigation

US10-11-2017

Resolving complex legal disputes and explaining technical concepts in a courtroom are all part of the job for Regeneron’s Larry Coury, who talks to LSIPR about life as senior director of dispute resolution.

Showing 81 to 90 of 314 results

LSIPR